EP0804925A1 — Liposome with increased retention volume
Assigned to Daiichi Pharmaceutical Co Ltd · Expires 1997-11-05 · 29y expired
What this patent protects
The present invention provides liposome preparations capable of efficiently holding water soluble substance particularly non-electrolytic water soluble substances. Liposomes and suspensions thereof comprising multilamellar liposomes characterized in that the liposome membra…
USPTO Abstract
The present invention provides liposome preparations capable of efficiently holding water soluble substance particularly non-electrolytic water soluble substances. Liposomes and suspensions thereof comprising multilamellar liposomes characterized in that the liposome membrane is formed from a neutral phospholipid comprising a substantially saturated fatty acid residue a charged phospholipid comprising a substantially saturated fatty acid residue, ratio of said neutral phospholipid and charged phospholipid is 200:1 to 3:1, weighted average particle size of the liposome is 50 nm to 3,000 nm, and an encapsulation capacity of the liposome (internal aqueous phase (volume)/lipids (weight)) is at least 5 mℓ/g. The present liposome preparation can encapsulate an aqueous solution of a non-electrolytic water soluble substances with an encapsulation capacity (internal aqueous phase/lipids) of at least 5 mℓ/g.
Drugs covered by this patent
- Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.